Our Pricing

Low Dose Wegovy vs Mounjaro: Compare Both Options

Published on: June 03, 2026

Choosing between low dose Wegovy vs Mounjaro UK options requires understanding how each medication performs at maintenance levels. At Cured Pharmacy, our UK-registered clinical team helps patients navigate the differences between semaglutide and tirzepatide for sustained weight management, with transparent pricing and expert prescriber support throughout your treatment journey.

Understanding Low Dose Wegovy for Weight Maintenance

Wegovy (semaglutide) follows a structured dose escalation protocol, typically reaching a maintenance dose of 1.7mg or 2.4mg weekly [1]. Many patients ask whether they can remain on lower doses—such as 0.5mg or 1mg—for long-term weight maintenance after achieving their initial goals.

Clinical evidence from the STEP trials demonstrates that the full 2.4mg dose produces optimal weight loss outcomes, with participants achieving an average 14.9% body weight reduction over 68 weeks [1]. However, some patients may experience adequate weight maintenance on lower doses, particularly if they've already lost significant weight and are focusing on stabilisation rather than continued reduction.

The decision to stay on a lower Wegovy dose must be made in consultation with your UK prescriber, who will assess your individual response, side effect profile, and weight management goals. Some patients tolerate lower doses better whilst maintaining their weight loss, whilst others require the full therapeutic dose to prevent weight regain [2].

How Mounjaro Differs from Low Dose Wegovy

Mounjaro (tirzepatide) represents a distinct pharmacological approach as the UK's first dual GIP/GLP-1 receptor agonist [3]. Whilst Wegovy activates only the GLP-1 pathway, Mounjaro simultaneously targets both glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, producing enhanced metabolic effects.

The SURPASS-2 trial directly compared tirzepatide with semaglutide 1mg, demonstrating that Mounjaro's highest dose (15mg) produced significantly greater weight reduction—an average of 12.4kg compared to 6.2kg with semaglutide over 40 weeks [3]. This dual-action mechanism may offer advantages for patients who plateau on semaglutide-based treatments.

Mounjaro's dosing schedule also differs, with maintenance doses ranging from 5mg to 15mg weekly depending on individual response and tolerability. The lower starting doses (2.5mg) help minimise gastrointestinal side effects during the initial titration period, similar to Wegovy's escalation protocol [4].

Dual Receptor Activation Explained

The GIP receptor plays a crucial role in insulin secretion and may influence fat metabolism differently than GLP-1 alone [3]. This dual mechanism explains why patients on Mounjaro often experience greater appetite suppression and more substantial weight loss compared to single-pathway GLP-1 agonists, even at comparable doses.

Clinical Efficacy: Low Dose Wegovy vs Mounjaro UK Studies

When comparing low dose options, it's essential to examine real-world efficacy data. The STEP 1 trial showed that even participants who didn't reach the full 2.4mg Wegovy dose still achieved meaningful weight loss, though outcomes were dose-dependent [1]. Patients on 1.7mg experienced approximately 12-13% body weight reduction, compared to 14.9% at the full dose.

For Mounjaro, the SURMOUNT-1 trial demonstrated that even the mid-range 10mg dose produced an average 19.5% weight reduction over 72 weeks—exceeding the results seen with maximum-dose semaglutide [4]. The 15mg Mounjaro dose achieved up to 22.5% body weight reduction in clinical trials, representing the highest efficacy among currently licensed weight management medications in the UK.

These comparative data suggest that patients who struggle to tolerate or respond adequately to low dose Wegovy may achieve better outcomes by switching to Mounjaro, where even moderate doses produce substantial metabolic benefits. However, individual response varies considerably, and some patients thrive on lower-dose semaglutide with fewer side effects.

Weight Maintenance vs Active Loss Phase

The distinction between active weight loss and maintenance phases influences dosing decisions significantly. Patients who've achieved their target weight may find that a lower Wegovy dose (1mg or 1.7mg) suffices for maintenance, particularly when combined with lifestyle modifications. Your UK prescriber will monitor your weight trajectory and adjust dosing accordingly to prevent regain whilst minimising medication burden.

Side Effect Profiles: What to Expect on Lower Doses

Both Wegovy and Mounjaro share similar side effect profiles, predominantly gastrointestinal symptoms including nausea, vomiting, diarrhoea, and constipation [1][3]. These effects are typically dose-dependent, meaning lower doses generally produce milder symptoms.

Patients on low dose Wegovy (0.5mg to 1mg) often report better tolerability compared to the full 2.4mg dose, with nausea affecting approximately 20-30% of users at lower doses versus 44% at maximum dose [2]. This improved tolerability is a key reason some patients prefer to remain on sub-maximal doses for long-term maintenance.

Mounjaro's side effect incidence also correlates with dose escalation. The 5mg maintenance dose produces fewer gastrointestinal complaints than the 15mg dose, though the dual receptor mechanism may cause slightly different symptom patterns compared to semaglutide [4]. Some patients find Mounjaro's side effects more manageable despite higher efficacy, whilst others tolerate Wegovy better—individual variation is substantial.

Cost Considerations for Low Dose Wegovy vs Mounjaro UK

Pricing structures for weight loss medications vary across UK pharmacies, with dose strength significantly impacting overall treatment costs. At Cured Pharmacy, Mounjaro is available from £124.99, whilst Wegovy starts from £135.00, with final pricing determined by your prescribed dose and treatment duration.

Patients considering long-term maintenance on lower doses should factor in the cumulative cost over months or years. Whilst lower doses may reduce per-pen expenses, the total cost-effectiveness depends on whether the reduced dose maintains your weight loss adequately or whether you experience regain requiring dose escalation.

Some patients find that investing in a higher-dose, more efficacious treatment like Mounjaro ultimately proves more cost-effective than prolonged use of sub-optimal Wegovy doses that fail to prevent weight regain. Your UK prescriber can help evaluate the clinical and financial trade-offs based on your individual response pattern and weight management goals.

Transparent Pricing at Cured Pharmacy

Unlike many online services, Cured Pharmacy displays upfront pricing before your consultation, ensuring no hidden costs. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all dispensing, guaranteeing you receive genuine UK-licensed medications at the lowest prices in the UK market. All prescription treatments require a free online clinical assessment by our UK-registered prescribers, typically completed in under three minutes.

Making the Right Choice: Low Dose Wegovy vs Mounjaro for Your Needs

Selecting between low dose Wegovy and Mounjaro depends on multiple factors: your weight loss history, current BMI, side effect tolerance, budget, and whether you're in an active loss phase or maintenance period. Patients who've achieved significant weight loss on Wegovy and are now maintaining may find lower doses sufficient with proper lifestyle support.

Conversely, individuals who've plateaued on semaglutide or haven't reached their target weight may benefit from switching to Mounjaro's dual-action mechanism. The enhanced efficacy of tirzepatide can overcome resistance to single-pathway GLP-1 agonists, though this must be balanced against potential differences in side effect profiles and cost.

At Cured Pharmacy, our UK clinical team conducts thorough assessments to determine which medication and dose align with your medical history and weight management objectives. We monitor your progress and adjust treatment as needed, ensuring you receive optimal support throughout your journey. All consultations are conducted by UK-registered prescribers in compliance with MHRA and GPhC regulations, with discreet packaging and next-day delivery options available across the UK.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., Dicker, D., & STEP 4 Investigators. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., Stefanski, A., & SURMOUNT-1 Investigators. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary by individual and depend on multiple factors including diet, exercise, and adherence to treatment. Claims regarding efficacy are based on clinical trial data and may not reflect individual outcomes.